GlassScriptPhysician profile
Peter J Minkoff
NPI 1023090008
$2,275.27
in general payments reported to CMS, 2019-2025
26 companies · $47.76 in 2025
The $47.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $535 · 2021: $884 · 2022: $139 · 2023: $39.28 · 2024: $28.38 · 2025: $47.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $313.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $290.68 | 2019-2022 | |
| Abbvie INC. | $267.76 | 2021-2024 | |
| Amarin Pharma, INC. | $204.28 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $155.21 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $105.80 | 2019-2021 | |
| Lilly USA, LLC | $97.70 | 2019-2021 | |
| Pfizer INC. | $92.43 | 2019-2021 | |
| Allergan, INC. | $91.17 | 2019-2020 | |
| Amgen INC. | $73.39 | 2019-2022 | |
| Boston Scientific Corporation | $68.65 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Sanofi-Aventis U.S. LLC | $60.42 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $57.91 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $44.58 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $34.97 | 2021 | |
| Novo Nordisk INC | $33.25 | 2019-2021 | |
| Ibsa Pharma INC. | $24.40 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.13 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.67 | 2022 | |
| Si-Bone, INC. | $19.69 | 2019 | |
| Stryker Corporation | $19.06 | 2019 | |
| Abbott Laboratories | $16.15 | 2023 | Freestyle Libre 3 |
| Antares Pharma, INC. | $15.88 | 2021 | |
| Duchesnay USA Incorporated | $15.24 | 2019 | |
| Stimwave Technologies Incorporated | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Minkoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.